Cargando…

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)

BACKGROUND: ME1100 (arbekacin inhalational solution) is an aminoglycoside in clinical development for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Due to the increase in resistance of Staphylococcus aureus and Pseudomon...

Descripción completa

Detalles Bibliográficos
Autores principales:	VanScoy, Brian D, Lakota, Elizabeth A, Bhavnani, Sujata M, Giesel, Greg, Carranco, Ana I, Nagira, Yu, Ouchi, Shohei, Kondo, Kenichiro, Ambrose, Paul G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252722/ http://dx.doi.org/10.1093/ofid/ofy210.1210

Ejemplares similares

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Applications of the hollow-fibre infection model (HFIM) in viral infection studies
por: Kembou-Ringert, Japhette E, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model
por: VanScoy, B. D., et al.
Publicado: (2023)

Clinical Usefulness of Arbekacin
por: Lee, Jae Hoon, et al.
Publicado: (2016)

Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting
por: Sadouki, Zahra, et al.
Publicado: (2021)

The usefulness of arbekacin compared to vancomycin
por: Hwang, J.-H., et al.
Publicado: (2011)

1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1(st) - 3(rd) Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model
por: Lepak, Alexander, et al.
Publicado: (2023)

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)
por: Pires de Mello, Camilly P., et al.
Publicado: (2018)

1095. Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

Arbekacin as an Alternative Drug to Teicoplanin for the Treatment of MRSA Infection
por: Hwang, Ji-Hee, et al.
Publicado: (2016)

Mechanistic insights into translation inhibition by aminoglycoside antibiotic arbekacin
por: Parajuli, Narayan Prasad, et al.
Publicado: (2021)

Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM)
por: Louie, Arnold, et al.
Publicado: (2017)

The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species
por: Watanabe, Junko, et al.
Publicado: (2023)

Traditional PK-PD Indices for Efficacy – Can We Do Better?
por: Lakota, Elizabeth A, et al.
Publicado: (2017)

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
por: Lee, Ji-Young, et al.
Publicado: (2006)

Distribution of subtypes and immunophenotypic characterization of 1379 cases of paediatric acute leukaemia
por: Jamal, Saba, et al.
Publicado: (2021)

Time for Precision: A World Without Susceptibility Breakpoints
por: Bader, Justin C, et al.
Publicado: (2018)

1379. Caregiver Burden related to Rotavirus Gastroenteritis: a systematic literature review
por: Carias, Cristina, et al.
Publicado: (2020)

1379. Evaluation of Cardiovascular Disease Risk among People Living with HIV in Lebanon
por: Helou, Remie El, et al.
Publicado: (2023)

The Efficacy and Safety of Arbekacin and Vancomycin for the Treatment in Skin and Soft Tissue MRSA Infection: Preliminary Study
por: Hwang, Ji-Hee, et al.
Publicado: (2013)

Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus
por: Hwang, Ji-Hee, et al.
Publicado: (2015)

1281. An Evaluation of Tebipenem In Vitro Activity Against a Panel of Pseudomonas aeruginosa Isolates with Efflux, AmpC, and OprD Mutations
por: VanScoy, Brian D, et al.
Publicado: (2021)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

1379. Comparison of Inpatient Tuberculosis Screening Methods and Their Effect on Patient Duration in Airborne Isolation
por: Katherine. Theoktisto, Mary, et al.
Publicado: (2019)

Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase
por: Iwashita, Yoshiaki, et al.
Publicado: (2013)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies
por: Ohashi, Takashi, et al.
Publicado: (2022)

How to inform at‐risk relatives? Attitudes of 1379 Dutch patients, relatives, and members of the general population
por: Marleen van den Heuvel, Lieke, et al.
Publicado: (2019)

1263. Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
por: Avery, Lindsay M, et al.
Publicado: (2020)

2792. Determining the activity of imipenem/relebactam (I/R) plus aztreonam (ATM) against constitutive Pseudomonas derived cephalosporinase (PDC)- and metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa in a hollow fiber infection model (HFIM)
por: O’Donnell, J Nicholas, et al.
Publicado: (2023)

1379. Vaccination Rates among Liver Transplant Recipients at a Tertiary Care Hospital in Newark, NJ
por: Varughese, Tilly, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hr7786dh659rm1gejpr0p5dtve